GLP-1 Drugs Unlikely to Cause Thyroid Cancer, Review Finds
Researchers at the Clayman Thyroid Center reviewed clinical trials, adverse reports, and real-world data and found little to no evidence that GLP-1 receptor agonists (including Ozempic, Wegovy, and Mounjaro) raise the risk of thyroid cancer, including medullary thyroid cancer. Any uptick in diagnoses is likely due to detection bias from more frequent screening. While large population studies would help solidify certainty, current guidance aligns with avoiding GLP-1s only for people with personal or family histories of medullary thyroid cancer or MEN2.
